1. Search Result
Search Result
Results for "

Pyroptosis inhibitor

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

4

Peptides

13

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144226
    NLRP3/AIM2-IN-3
    5+ Cited Publications

    NOD-like Receptor (NLR) AIM2 Pyroptosis Inflammation/Immunology
    NLRP3/AIM2-IN-3 (compound 59) is a potent inhibitor with differential species specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. NLRP3/AIM2-IN-3 shows inhibitory efficacy against pyroptosis in THP-1 macrophages stimulated with LPS/nigericin, with an IC50 of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 disturbs the interaction of NLRP3 or AIM2 with the adaptor protein ASC and inhibited ASC oligomerization .
    NLRP3/AIM2-IN-3
  • HY-162150

    AZL-N

    Pyroptosis Inflammation/Immunology
    Azalamellarin N is an inhibitor of pyroptosis and has different inhibitory effects on different pyroptosis inducers. Azalamellarin N inhibits pyroptosis by targeting molecules that act upstream of NLRP3 inflammasome activation, rather than directly targeting components of the NLRP3 inflammasome. Inhibitory potency against different pyroptosis inducers: Nigericin (HY-127019) > R837 (HY-B0180) .
    Azalamellarin N
  • HY-111770
    2-Bromohexadecanoic acid
    2 Publications Verification

    2-Bromopalmitic acid; 2-Bromopalmitate

    Pyroptosis Infection Inflammation/Immunology Cancer
    2-Bromohexadecanoic acid (2-Bromopalmitate; 2-BP) is a palmitoylation inhibitor targeting DHHC (Asp-His-His-Cys) protein palmitoyltransferase. 2-Bromohexadecanoic acid inhibits palmitoylation of GSDME-C during pyroptosis and inhibits BAK/BAX-Caspase 3-GSDME pathway-mediated pyroptosis .
    2-Bromohexadecanoic acid
  • HY-42068

    (R)-Aspartic acid; D-(-)-Aspartic acid

    Pyroptosis Neurological Disease
    (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system .
    (-)-Aspartic acid
  • HY-124857

    7-Desacetoxy-6,7-dehydrogedunin

    PERK Inflammation/Immunology
    7DG (7-Desacetoxy-6,7-dehydrogedunin) is a protein kinase R (PKR) inhibitor. 7DG protects macrophages from lethal toxin-induced pyroptosis .
    7DG
  • HY-161043

    Pyroptosis Inflammation/Immunology
    ECDD-S16 is a potent inhibitor of pyroptosis. ECDD-S16 inhibits surface and endosomal TLR ligands activated pyroptosis in Raw264.7 cells .
    ECDD-S16
  • HY-173234

    Pyroptosis Cardiovascular Disease
    GI-Y2 is an inhibitor of GSDMD and can inhibit Pyroptosis of macrophages induced by oxidized low-density lipoprotein (ox-LDL). In vivo, GI-Y2 can dose-dependently reduce atherosclerotic plaques in ApoE-/- mice and decrease the lesion size and fibrosis degree of the aortic root. GI-Y2 is expected to be used in the research of pyroptosis and cardiovascular diseases, such as atherosclerosis .
    GI-Y2
  • HY-170529

    NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    NLRP3-IN-61 (Compound 1) is an inhibitor for NLRP3. NLRP3-IN-61 inhibits pyroptosis in THP-1 cell with an IC50 of 12.6 nM, inhibits IL-β release with an IC50 of 25.3 nM .
    NLRP3-IN-61
  • HY-170530

    NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    NLRP3-IN-62 (Compound 1) is an inhibitor for NLRP3. NLRP3-IN-62 inhibits pyroptosis in THP-1 cell with an IC50 of 0.7 nM, inhibits IL-β release with an IC50 of 108.5 nM .
    NLRP3-IN-62
  • HY-N9921

    Pyroptosis NOD-like Receptor (NLR) Inflammation/Immunology
    Antcin A is a potent NLRP3 inhibitor that inhibits the assembly and activation of the NLRP3 inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .
    Antcin A
  • HY-42068R

    Pyroptosis Neurological Disease
    (-)-Aspartic acid (Standard) is the analytical standard of (-)-Aspartic acid. This product is intended for research and analytical applications. (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system .
    (-)-Aspartic acid (Standard)
  • HY-B0621
    Triclabendazole
    4 Publications Verification

    CGA89317

    Parasite Caspase Bcl-2 Family PARP Pyroptosis Infection
    Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole
  • HY-D2376

    Fluorescent Dye Cancer
    BH-Vis is a two-photon fluorescent probe that inhibits cell plasma membrane (CPM). BH-Vis has great potential to accurately identify pyroptosis at the cellular level during AAA development in the mouse abdominal aortic aneurysm AAA model .
    BH-Vis
  • HY-149604
    NLRP3-IN-21
    1 Publications Verification

    NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .
    NLRP3-IN-21
  • HY-156034

    NLRP3-IN-19

    NOD-like Receptor (NLR) Inflammation/Immunology
    JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
    JT001
  • HY-156034A

    NLRP3-IN-19 sodium

    NOD-like Receptor (NLR) Inflammation/Immunology
    JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
    JT001 sodium
  • HY-155053

    Flavivirus DNA/RNA Synthesis Inflammation/Immunology
    ZIKV-IN-6 (compound 22) is an inhibitor of Zika virus (ZIKV), with low cytotoxicity (CC50>50 μM). ZIKV-IN-6 binds to ZIKV RdRp directly and inhibits viral RNA synthesis by ZIKV NS5. ZIKV-IN-6 suppresses the excessive inflammatory response and pyroptosis .
    ZIKV-IN-6
  • HY-170364

    NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    NLRP3-IN-60 (Compound 39) is the orally active inhibitor for NLRP3. NLRP3-IN-60 inhibits pyroptosis with an IC50 of 13 nM in THP-1 cell. NLRP3-IN-60 inhibits IL-1β release with an IC50 of 225 nM in human whole blood .
    NLRP3-IN-60
  • HY-163179

    NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    NLRP3-IN-28 (compound N77) is a potent inhibitor of NLRP3. NLRP3-IN-28 inhibits Nigericin (HY-127019)-induced pyroptosis with an EC50 of 0.07μM. NLRP3-IN-28 alleviates the inflammatory reaction in vivo .
    NLRP3-IN-28
  • HY-164304

    Pyroptosis Interleukin Related NOD-like Receptor (NLR) Cardiovascular Disease Inflammation/Immunology
    INF 195 is an NLRP3 inhibitor. INF 195 can inhibit NLRP3 driven macrophage pyroptosis and IL-1β release, with an EC50 value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury .
    INF 195
  • HY-159589

    Btk Apoptosis Cancer
    BTK-IN-37 (compound 8d) is a BTK inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with Ki and IC50 of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis .
    BTK-IN-37
  • HY-P3496

    Pyroptosis Inflammation/Immunology
    Pep19-2.5 is an synthetic and antitoxin peptide, blocks the intracellular endotoxin signaling cascade. Pep19-2.5 inhibits signaling of lipopeptides (LP) and lipopolysaccharides (LPS) mediated by transmembrane and cytosolic pattern recognition receptors (PRRs). The signaling cascades lead to inflammation and cell pyroptosis .
    Pep19-2.5
  • HY-N15380

    PARP Reactive Oxygen Species Caspase Apoptosis Pyroptosis Cancer
    4,4′-Secalonic acid D (Compound 12) is a PARP1 inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting PARP1. 4,4′-Secalonic acid D has anti-tumor activity .
    4,4′-Secalonic acid D
  • HY-N12482

    NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-27 (compound 1) is an inhibitor of NLRP3 with an IC50 value of 0.74 μM. NLRP3 reduces inflammasome-induced pyroptosis in J774A.1 cells. NLRP3-IN-27 can be isolated from Callicarpa arborea Rox .
    Callicarboric acid A
  • HY-B0621R

    Parasite Caspase Bcl-2 Family PARP Pyroptosis Infection
    Triclabendazole (Standard) is the analytical standard of Triclabendazole. This product is intended for research and analytical applications. Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole (Standard)
  • HY-16990
    Ac-YVAD-cmk
    10+ Cited Publications

    Caspase-1 inhibitor II

    Caspase Inflammation/Immunology
    Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective caspase-1 (IL-1beta converting enzyme, ICE)) inhibitor with neuroprotective and anti-inflammatory effects. Ac-YVAD-cmk effectively suppresses the expression of IL-1β and IL-18. Ac-YVAD-cmk inhibits pyroptosis in many diseases .
    Ac-YVAD-cmk
  • HY-156374

    NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD. D359-0396 alleviates EAE, and also improves survival after septic shock in mice .
    D359-0396
  • HY-B0621S

    CGA89317-d3

    Parasite Microtubule/Tubulin Isotope-Labeled Compounds Others
    Triclabendazole-d3 is the deuterium labeled Triclabendazole (HY-B0621). Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica .
    Triclabendazole-d3
  • HY-P3434

    Pyroptosis Inflammation/Immunology
    Ac-FEID-CMK is a potent zebrafish-specific GSDMEb-derived peptide inhibitor. Ac-FEID-CMK can attenuate the mortality and kidney injury during septic shock. Ac-FEID-CMK inhibits pyroptosis and attenuates septic AKI (acute kidney injury) in vivo. Ac-FEID-CMK can suppress the caspy2-mediated noncanonical inflammasome pathway .
    Ac-FEID-CMK
  • HY-172788

    Pyroptosis NF-κB Inflammation/Immunology
    NLRP3-IN-78 (compound 21) is a NLRP3 inhibitor with the inhibition rate of 46.72% in GSDMD-induced pyroptosis at 5 μM. NLRP3-IN-78 binds to the NLRP3 protein and inhibits GSDMD-NT oligomerization. NLRP3-IN-78 also inhibits GSDMD cleavage, and upstream NF-κB signaling, demonstrating its anti-inflammatory activity .
    NLRP3-IN-78
  • HY-169227

    Pyroptosis NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-55 (Compound 19) is a potent NLRP3 inhibitor (IC50 = 0.34 μM). NLRP3-IN-55 directly targets the NLRP3 protein (KD = 0.45 μM), blocking the assembly and activation of the NLRP3 inflammasome, leading to anti-inflammatory effects and inhibition of cellular pyroptosis .
    NLRP3-IN-55
  • HY-P3434A

    Pyroptosis Inflammation/Immunology
    Ac-FEID-CMK TFA is a potent zebrafish-specific GSDMEb-derived peptide inhibitor. Ac-FEID-CMK TFA can attenuate the mortality and kidney injury during septic shock. Ac-FEID-CMK TFA inhibits pyroptosis and attenuates septic AKI (acute kidney injury) in vivo. Ac-FEID-CMK TFA can suppress the caspy2-mediated noncanonical inflammasome pathway .
    Ac-FEID-CMK TFA
  • HY-157082

    Enterovirus Infection
    ZHSI-1 is an EV71 (Enterovirus 71) inhibitor that inhibits EV71/CVA16 replication and virus-induced pyroptosis associated with viral pathogenesis. ZHSI-1 effectively prevents EV71 infection in neonatal and young mice in animal models. ZHSI-1 can be used to study viral infections such as hand, foot and mouth disease (HFMD) .
    ZHSI-1
  • HY-N0639

    HBV Pyroptosis Carbonic Anhydrase Infection Inflammation/Immunology
    Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
    Punicalin
  • HY-158111

    NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-34 (Compound T10) is an inhibitor for NLRP3 inflammasome. NLRP3-IN-34 inhibits ROS production, NLRP3 inflammasome-dependent IL-1β production (IC50 is 0.48 μM in cells J774A.1), and inhibits pyroptosis. NLRP3-IN-34 exhibits anti-inflammatory activity against DSS-induced peritonitis .
    NLRP3-IN-34
  • HY-132591
    Inclisiran
    2 Publications Verification

    ALN-PCSsc

    PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related Cardiovascular Disease Metabolic Disease
    Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .
    Inclisiran
  • HY-132591A
    Inclisiran sodium
    2 Publications Verification

    ALN-PCSsc sodium

    PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related Cardiovascular Disease Metabolic Disease
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .
    Inclisiran sodium
  • HY-168927

    Apoptosis Pyroptosis Cancer
    Apoptosis inducer 36 (Compound 42) exhibits anti-leukemic activity through reduction of leukemia stem cells (LSCs) and induction of differentiation. Apoptosis inducer 36 inhibits the proliferation of AML cells, arrests cell cycle at G1 phase, and induces PANoptosis including apoptosis, pyroptosis and necrosis. Prodrug of apoptosis inducer 36 exhibits orally active antitumor efficacy in mouse model .
    Apoptosis inducer 36
  • HY-164853

    Pyroptosis NOD-like Receptor (NLR) ERK FGFR AMPK Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis .
    Kanglexin
  • HY-B0240
    Disulfiram
    85+ Cited Publications

    Tetraethylthiuram disulfide; TETD

    Aldehyde Dehydrogenase (ALDH) Interleukin Related Pyroptosis Apoptosis Cuproptosis Metabolic Disease Cancer
    Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu 2+ increases intracellular ROS levels and induces cuproptosis .
    Disulfiram
  • HY-138071

    8αTGH

    STAT Pyroptosis Apoptosis Reactive Oxygen Species c-Myc Bcl-2 Family TrxR Cancer
    8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo .
    8α-Tigloyloxyhirsutinolide 13-O-acetate
  • HY-B0240R

    Tetraethylthiuram disulfide (Standard); TETD (Standard)

    Reference Standards Aldehyde Dehydrogenase (ALDH) Interleukin Related Pyroptosis Apoptosis Cuproptosis Metabolic Disease Cancer
    Disulfiram (Standard) is the analytical standard of Disulfiram. This product is intended for research and analytical applications. Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram + Cu 2+ increases intracellular ROS levels triggering apoptosis of ovarian cancer stem cells [1-6].
    Disulfiram (Standard)
  • HY-161834

    Pyroptosis Aquaporin NOD-like Receptor (NLR) p38 MAPK Infection Metabolic Disease Inflammation/Immunology
    RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H 2O 2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .
    RG100204
  • HY-N0639R

    HBV Pyroptosis Carbonic Anhydrase Infection Inflammation/Immunology
    Punicalin (Standard) is the analytical standard of Punicalin. This product is intended for research and analytical applications. Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
    Punicalin (Standard)
  • HY-N0272R

    Others Inflammation/Immunology
    Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis .
    Eleutheroside E (Standard)
  • HY-13453
    BAY 11-7082
    Maximum Cited Publications
    343 Publications Verification

    BAY 11-7821

    IKK Deubiquitinase Autophagy Apoptosis NF-κB Inflammation/Immunology Cancer
    BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells .
    BAY 11-7082
  • HY-P10939

    Caspase Pyroptosis Inflammation/Immunology Cancer
    Ac-DMLD-CMK is a polypeptide targeting the mouse caspase 3-Gsdme signaling pathway. Ac-DMLD-CMK can specifically inhibit the activation of caspase 3 and Gsdme. Ac-DMLD-CMK blocks the cleavage of Gsdme by caspase 3, inhibits the occurrence of pyroptosis, thereby reducing renal tubular epithelial cell injury and the secretion of inflammatory cytokines. Ac-DMLD-CMK reduces the levels of serum creatinine and blood urea nitrogen in mice induced by Cisplatin (HY-17394) and alleviates the deterioration of kidney function. Ac-DMLD-CMK is promising for research of chemotherapy drug-induced nephrotoxicity .
    Ac-DMLD-CMK
  • HY-149478

    NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    JT002 is an orally active and selective NLRP3 inflammasome assembly inhibitor. JT002 reduces NLRP3-dependent proinflammatory cytokine (such as IL-1β, IL-1α, IL-18) production and pyroptosis. JT002 blocks NLRP3 inflammasome complex formation. JT002 reduces airway hyperresponsiveness and airway neutrophilia in mice. JT002 can be used for the study of a variety of inflammatory diseases, such as Muckle-Wells syndrome (MWS) .
    JT002
  • HY-172885

    DNA/RNA Synthesis MicroRNA Apoptosis Pyroptosis Cancer
    TRBP-IN-1 (Compound 13j) is an orally active TAR RNA binding protein 2 (TRBP) inhibitor (IC50: 12.72 μM). TRBP-IN-1 has significant anti-hepatocellular carcinoma (HCC) activity and can inhibit the proliferation and metastasis of HCC cells (HCCLM3 cells (IC50: 18.96 μM); SK-Hep-1 cells (IC50: 16.45 μM)). TRBP-IN-1 regulates miRNA biogenesis and inhibits oncogenic miRNA expression by targeting TRBP. TRBP-IN-1 induces apoptosis and pyroptosis in HCC cells by inhibiting the level of miRNA. TRBP-IN-1 can be used for targeted therapy research of HCC .
    TRBP-IN-1
  • HY-N0696
    Sipeimine
    2 Publications Verification

    Imperialine

    PI3K NF-κB Akt NOD-like Receptor (NLR) Pyroptosis Ferroptosis Inflammation/Immunology
    Sipeimine (Imperialine) is an inhibitor targeting the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome, which can competitively bind to PI3K and p65. Sipeimine inhibits PI3K/AKT phosphorylation, blocks NF-κB nuclear translocation and NLRP3 inflammasome activation. Sipeimine exerts anti-inflammatory activities, inhibits pyroptosis and ferroptosis, and protects the extracellular matrix. Sipeimine can reduce cartilage degradation and synovial inflammation in osteoarthritis and improve PM2.5-induced lung injury. Sipeimine is mainly used in the study of anti-inflammatory and degenerative diseases .
    Sipeimine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: